Stock code: 688139 Stock abbreviation: Haier Biotech Announcement No.: 2024-044

Announcement of Qingdao Haier Biomedical Co., Ltd. on the general election of the board of directors and the board of supervisors

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Qingdao Haier Biomedical Co., Ltd. (hereinafter referred to as the "Company" or "Haier Bio") The term of the second board of directors and board of supervisors is about to expire, in accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and the "Articles of Association" and other relevant provisions, the company carries out the general election of the board of directors and the board of supervisors, and hereby announces the general election of the board of directors and the board of supervisors as follows:

1. General election of the board of directors

The company held the 21st meeting of the second board of directors on July 3, 2024, and deliberated and approved the "Proposal on the General Election of the Board of Directors and the Election of Non-Independent Directors" and the "Proposal on the General Election of the Board of Directors and the Election of Independent Directors". Ms. Chen Jie is a candidate for non-independent director of the third board of directors of the Company (please refer to the attachment for details), and Mr. Huang Sheng, Mr. Niu Jun and Mr. Xu Ming are nominated as candidates for independent directors of the third board of directors of the Company (please refer to the attachment for details of resume), among which Mr. Huang Sheng is an accounting professional.

According to the relevant regulations, the candidates for independent directors of the company shall be reviewed by the Shanghai Stock Exchange without objection before they can be submitted to the general meeting of shareholders of the company for deliberation. The Company will convene the first extraordinary general meeting of shareholders in 2024 to consider the re-election of the Board of Directors, in which the election of non-independent directors and independent directors will be carried out by cumulative voting system respectively. The directors of the third board of directors of the company will take office for a term of three years from the date of deliberation and approval of the first extraordinary general meeting of shareholders in 2024.

2. The general election of the board of supervisors

The company held the 19th meeting of the second board of supervisors on July 3, 2024, deliberated and passed the "Proposal on the General Election of the Board of Supervisors and the Election of Non-employee Representative Supervisors", and agreed to nominate Ms. Jiang Lan and Ms. Guo Congzhao as candidates for non-employee representative supervisors of the third board of supervisors (see the attachment for details), and submitted them to the company's first extraordinary general meeting of shareholders in 2024 for deliberation. The above-mentioned non-employee representative supervisor will form the third board of supervisors of the company together with an employee representative supervisor elected by the company's employee representative congress. The non-employee representative supervisors of the third board of supervisors are elected by cumulative voting system and will take office for a term of three years from the date of deliberation and approval of the company's first extraordinary general meeting of shareholders in 2024.

3. Other notes

The qualifications of the above-mentioned candidates for directors and supervisors meet the requirements of relevant laws, administrative regulations and normative documents for the qualifications of directors and supervisors, and there is no circumstance that they are not allowed to serve as directors or supervisors of the company as stipulated in the Company Law and the Articles of Association, and such candidates for directors and supervisors have not been subject to administrative punishment by the China Securities Regulatory Commission or disciplinary action by the exchange, and there are no other circumstances that the Shanghai Stock Exchange determines are not suitable to serve as directors or supervisors of listed companies. In addition, the educational background and work experience of the candidates for independent directors are all qualified to serve as independent directors, and meet the relevant requirements for the qualifications and independence of independent directors in the Measures for the Administration of Independent Directors of Listed Companies and the Company's Independent Director System. In order to ensure the normal operation of the board of directors and the board of supervisors of the company, the second board of directors and the board of supervisors will still perform their duties in accordance with the relevant provisions of the Company Law and the Articles of Association before the first extraordinary general meeting of shareholders of the company in 2024 deliberates and approves the above-mentioned re-election matters.

The announcement is hereby made.

Board of Directors of Qingdao Haier Biomedical Co., Ltd

July 4, 2024

P.S

Biography of Candidate Non-Independent DirectorMs. Tan Lixia, Chinese nationality, no right of permanent residence abroad, born in September 1970, bachelor's degree in economics from Central University of Finance and Economics, MBA from China Europe International Business School, senior professional research degree in applied finance from the University of Geneva, Switzerland, global chartered management accountant (CIMA), senior international certified internal controller (CICP), and an expert enjoying special government allowances from the State Council. Ms. Tan Lixia joined Haier Group in August 1992 and has successively served as the head of the Overseas Promotion Department, the head of the Financial Management Department, the chief financial officer, the vice president and the senior vice president of Haier Group, and is currently the vice chairman of the board of directors and executive vice president of Haier Group, the chairman of the board of directors of the company since July 2018, and the chairman of Yingkang Life Science and Technology Co., Ltd. since May 2019. Currently, Ms. Tan Lixia also serves as the Vice President of the China Women Entrepreneurs Association, a standing member of the 13th Executive Committee of the All-China Women's Federation, and a member of the 13th Shandong Provincial Committee of the Chinese People's Political Consultative Conference. Ms. Tan Lixia has been awarded honorary titles or awards such as "2006 China Chief Accountant of the Year", "China's Top 10 Economic Women of the Year" (2006), "National Outstanding Entrepreneur (2013-2014)", "First Prize of Light Industry Enterprise Management Modernization Innovation Achievement" (2013 and 2014), "National 38 Red Flag Bearer" (2015), "Outstanding Female Entrepreneur of Shandong Province" (2023), "National May Day Labor Medal" (2024) and other honorary titles or awards.

As of the disclosure date, Ms. Tan Lixia did not hold any shares in the Company. Ms. Tan Lixia has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been identified by the China Securities Regulatory Commission as a person prohibited from entering the market and is still in the prohibition period, nor has he been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a dishonest person subject to execution announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations. Mr. Zhou Yunjie, Chinese nationality, no right of permanent residence abroad, born in November 1966, holds a doctorate degree in business administration from Xi'an Jiaotong University, and is a deputy to the 12th, 13th and 14th National People's Congress. Mr. Zhou Yunjie joined Haier Group in July 1988 and successively served as Deputy Factory Director, Factory Director, Quality Manager, Deputy General Manager and General Manager of Qingdao Haier Refrigerator Co., Ltd. from April 1993 to July 1999, Head of Refrigerator Electrician Headquarters of Haier Group, and from July 1999 to November 2021, he successively served as Trainee Vice President, Vice President, Senior Vice President, Chief Marketing Officer, Executive Vice President, Rotating President of Haier Group Co., Ltd. President and Vice Chairman of the Board of Directors (Period: Chairman of the Board of Directors of Haier Electric Appliance Group Co., Ltd. from June 2013 to December 2020), Chairman of the Board of Directors and Chief Executive Officer of Haier Group since November 2021. He has been a director of the Company since July 2018. Mr. Zhou was awarded the "National Outstanding Quality Management Worker" (1999), the "7th National Special Enterprise Management Modernization Innovation Achievement" (2001), the "National Information Industry System Model Worker" (2003), the "2003 National Outstanding Manager of Customer Satisfaction", "China's Famous Enterprise Planner" (2004), the "National May Day Labor Medal" (2017), the "National Outstanding Communist Party Member" (2021), and the "12th Yuan Baohua Enterprise Management Gold Award" (2022) and other honorary titles or awards.

As of the disclosure date, Mr. Zhou Yunjie did not hold any shares of the Company. Mr. Zhou Yunjie has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that is prohibited from serving as a director of the company under the Company Law, there is no circumstance that the CSRC has determined that it is prohibited from entering the market and is still in the prohibition period, and there is no certificate

The

securities exchange has publicly determined that it is not suitable to serve as a director of a listed company, has not been punished or punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a judgment defaulter announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and provisions. Mr. Liu Zhanjie, Chinese nationality, no right of permanent residence abroad, born in July 1970, Ph.D. in refrigeration and cryogenic engineering from University of Shanghai for Science and Technology, MBA from Antai College of Economics and Management, Shanghai Jiao Tong University, and an expert enjoying special government allowance from the State Council. Mr. Liu Zhanjie served as the director of the Cryogenic Technology Research Institute of Haier Group from May 2001 to October 2005, and has been the director and general manager of Qingdao Haier Biomedical Co., Ltd. since October 2005. Mr. Liu Zhanjie has also held various positions in various public institutions, including a member of the National Technical Committee for Refrigeration Standardization since 2003, a member of the Biobank Branch of the China Association of Pharmaceutical Biotechnology since 2009, a member of the National Technical Committee for the Standardization of Medical Device Quality Management and General Requirements since 2018, a member of the National Technical Committee for Standardization of Measurement, Control and Laboratory Electrical Equipment Safety since 2018, and a member of the National Technical Committee for Standardization of Measurement, Control and Laboratory Electrical Equipment Safety since 2018. Since 2021, he has served as the vice chairman of the second committee of the Organizational Sample Bank and Translational Medicine Professional Committee of Shandong Medical Doctor Association, and since 2023, he has served as the vice chairman of the Biological Resources and Facility Resources Professional Committee of the China Association for Standardization. As a well-known scholar in China, Mr. Liu Zhanjie was awarded the second prize of the National Science and Technology Progress Award in 2013, the "Expert of Taishan Scholars Climbing Program" and the "National Millions of Talents Project - Young and Middle-aged Experts with Outstanding Contributions" in 2015, the "Young and Middle-aged Leading Talents in Science and Technology Innovation of the Innovative Talent Promotion Program" of the Ministry of Science and Technology of the People's Republic of China in 2016, the "Third Batch of National 'Ten Thousand Talents Program' Leading Talents in Science and Technology Innovation" in 2018, and the "Blue Huizhi Double Hundred Talents" in the Shandong Peninsula National Independent Innovation Demonstration Zone. In 2019, he won the "Qilu Outstanding Talent Nomination Award" and the "Qingdao Science and Technology Highest Award", the "Qingdao Science and Technology Progress First Prize" in 2018 and 2020, the "Shandong Science and Technology Progress First Prize" and "Qingdao Most Beautiful Science and Technology Worker" in 2021, the "7th Shandong Enterprise Management Innovation Achievement Award" in 2022, and the "Qilu Most Beautiful Science and Technology Worker" in 2023.

As of the disclosure date, Mr. Liu Zhanjie held 62,000 shares of the company. Mr. Liu Zhanjie has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been identified by the China Securities Regulatory Commission as a person prohibited from entering the market and is still in the prohibition period, nor has he been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a dishonest person subject to execution announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations.

Ms. Gong Wenwen, Chinese nationality, no right of permanent residence abroad, born in March 1980, holds a bachelor's degree in accounting and finance and a bachelor's degree in management and economics from Wuhan University. Ms. Gong Wenwen joined Haier Group in July 2002 and served as the financial manager of the washing machine department (Qingdao) of Haier Group from June 2007 to October 2009. From November 2009 to October 2015, he served as the senior strategy manager of the financial management department of Haier Group; Since November 2015, he has served as the strategic director of Haier Group (Qingdao) Jinying Holdings Co., Ltd., since September 2020, and as a director of the company since July 2021. Since 2022, he has served as a member of the second standing committee of the International Medical Service Committee of the Chinese Hospital Association. Ms. Gong Wenwen has led the team to win honorary titles such as "Shandong Province 38 Red Flag Collective" (2020) and "National Women's Civilization Post" (2022).

As of the disclosure date, Ms. Gong Wenwen did not hold any shares of the Company. Ms. Gong Wenwen has no relationship with other directors, supervisors and senior management of the Company. There is no prohibition on serving as a director of a company under the Company Law

In the form, there is no circumstance that has been determined by the China Securities Regulatory Commission to be a person prohibited from entering the market and is still in the prohibition period, nor has there been a situation where the stock exchange has publicly determined that it is not suitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, does not belong to the judgment defaulter announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations.

Mr. Wang Wenfu, Chinese nationality, no right of permanent residence abroad, born in February 1976, graduated from Northwest Institute of Light Industry, intermediate engineer. He joined Haier Group in November 2006 and served as the regional director of Qingdao Haier Biomedical from November 2006 to December 2016. From January 2017 to December 2019, he served as the industry director of Qingdao Haier Biomedical Biospecimen Network; Since January 2020, he has served as the domestic marketing director of Qingdao Haier Biomedical, the deputy general manager of the company since March 2020, and the director of the company since April 2021.

As of the disclosure date, Mr. Wang Wenfu held 14,000 shares of the company. Mr. Wang Wenfu has no relationship with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been identified by the China Securities Regulatory Commission as a person prohibited from entering the market and is still in the prohibition period, nor has he been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a dishonest person subject to execution announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations.

Ms. Chen Jie, Chinese nationality, no right of permanent residence abroad, born in January 1963, holds a bachelor's degree in applied chemistry from Tianjin University and a master's degree in business administration from Cheung Kong Graduate School of Business. Ms. Chen Jie served as a R&D personnel of Plant 798 from 1985 to 1989, an employee of the Supply and Marketing Manager Department of Beijing Nuclear Industry Supplies from 1989 to 1996, the chief representative of Thermo Labsystem Division from 1996 to 1997, the general manager of Thermo Bioscience Technologies Division China from 1998 to 2001, and Thermo from 2002 to 2011 Marketing Director of Fisher Scientific (Laboratory Products Group), Commercial Director of Thermo Lab Solutions Group from 2012 to 2013, National Business Development Manager of Beijing Branch of Thermo Fisher Scientific (China) Co., Ltd. from 2015 to September 2018, Chairman and General Manager of Beijing Jinguoke Biomedical Engineering Technology Co., Ltd. since May 2019. Since August 2018, he has served as an independent director of the Company.

As of the disclosure date, Ms. Chen Jie did not hold any shares in the Company. Ms. Chen Jie has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been identified by the China Securities Regulatory Commission as a person prohibited from entering the market and is still in the prohibition period, nor has he been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a dishonest person subject to execution announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations.

Biographies of candidates for independent directors

Mr. Huang Sheng, Chinese nationality, no right of permanent residence abroad, born in June 1977, holds a Ph.D. in economics from the University of Washington (St. Louis), a master's degree in economics from the University of Cambridge, and a bachelor's degree in history and economics from Peking University. He was an Assistant Professor of Finance at Singapore Management University from July 2009 to June 2017, an Associate Professor of Finance at China Europe International Business School (CEIBS) from July 2017 to December 2022, and a Professor of Finance at CEIBS since January 2023. From February 2018 to June 2024, he served as the holding stock of Guoxin Culture

Independent director of a limited company. Since July 2020, he has served as an independent director of SinoPac Bank (China) Co., Ltd. From September 2020 to March 2022, he served as an independent director and convener of the audit committee of Dongguan Jingnuo Environmental Technology Co., Ltd. Since June 2021, he has served as an independent director of Guangzhou Langguo Electronic Technology Co., Ltd. Since October 2021, he has served as an independent director of Beijing Worthbuy Technology Co., Ltd. As at the date of disclosure, Mr. Huang Sheng did not hold any shares of the Company. Mr. Huang Sheng has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been identified by the China Securities Regulatory Commission as a person prohibited from entering the market and is still in the prohibition period, nor has he been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a dishonest person subject to execution announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations. Mr. Niu Jun, Chinese nationality, no right of permanent residence abroad, born in December 1952, is a doctor of medicine from the School of Medicine of Shandong University and a doctor of medicine from the School of Medicine of the University of Newcastle. Mr. Niu Jun studied for a doctorate degree in medicine and postdoctoral research at the University of Newcastle School of Medicine in Australia from June 1993 to June 2004, and was a former professor of surgery at Shandong University, deputy director of the Department of General Surgery of Qilu Hospital of Shandong University, and director of the Institute of Laparoscopic Minimally Invasive Surgery of Shandong University from August 2004 to December 2017. After retiring in 2017, he has been rehired as the chief physician of the Department of General Surgery of Qilu Hospital. At the same time, Mr. Niu Jun also serves as a standing committee member of the Tissue Biobank Branch of the China Medical Biotechnology Association and the chairman of the Shandong Biobank and Translational Medicine Professional Committee of the Chinese Medical Doctor Association. Mr. Niu Jun has won the first prize of Shandong Science and Technology Progress Award, China Physician Award and other honors.

As of the Disclosure Date, Mr. Niu Jun did not hold any shares of the Company. Mr. Niu Jun has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been identified by the China Securities Regulatory Commission as a person prohibited from entering the market and is still in the prohibition period, nor has he been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, is not a dishonest person subject to execution announced by the Supreme People's Court, and meets the requirements of the Company Law and other relevant laws, regulations and regulations. Mr. Xu Ming, Chinese nationality, no right of permanent residence abroad, born in August 1969, holds a Ph.D. in industrial economics from Fudan University and a postdoctoral fellow in strategic management at Guanghua School of Management, Peking University. He is currently a researcher in the Department of Global Health, School of Public Health, Peking University. He has worked in the Global Fund to Fight AIDS, Tuberculosis and Malaria, Nanjing Nuovezan Biotechnology Co., Ltd., China Chamber of Commerce for Import and Export of Medicines and Health Products, United Nations Iraq-Kuwait Observation Mission and the Chinese Embassy in South Korea. He has published more than 100 papers and articles in the fields of global public health, international development assistance, pharmaceutical industry competitiveness, international drug administration and enterprise internationalization, and has written many monographs and co-edited books. As of the disclosure date, Mr. Xu Ming did not hold any shares of the Company. Mr. Xu Ming has no relationship with other directors, supervisors and senior management of the Company. There is no circumstance that he is not allowed to serve as a director of a company under the Company Law, there is no circumstance that he has been determined by the China Securities Regulatory Commission to be a person prohibited from entering the market and is still in the prohibition period, and there is no circumstance that he has been publicly determined by the stock exchange to be unsuitable to serve as a director of a listed company, and has not been subject to the China Securities Regulatory Commission or the stock exchange

and other relevant departments to punish and punish judgment defaulters, who are not judgment defaulters announced by the Supreme People's Court, and meet the requirements of the "Company Law" and other relevant laws, regulations and provisions.

Resume of Candidate Supervisor Ms. Jiang Lan, Chinese nationality, no right of permanent residence abroad, born in July 1981, with the title of intermediate accountant. Ms. Jiang Lan joined Haier Group in July 2003 and has held financial management positions in the financial management department of Haier Air Conditioning Plant, the financial strategy department and finance company of Haier Group, the senior strategic analyst of the financial strategy department of Haier Group from February 2010 to December 2012, and the head of strategic management of the strategy department of Haier Group (Qingdao) Jinying Holdings Co., Ltd. from January 2013 to February 2019. From March 2019 to September 2022, he served as the head of strategic finance of Haier Group (Qingdao) Jinying Holdings Co., Ltd., from October 2022 to September 2023, as the chief financial officer of Haier Group (Qingdao) Jinying Holdings Co., Ltd., since September 2023, and as the chairman of the board of supervisors of the company since April 2023.

As of the disclosure date, Ms. Jiang Lan held 2,800 shares of the company. Ms. Jiang Lan has no relationship with other directors, supervisors and senior management of the Company. There is no circumstance that the Company Law prohibits him from serving as a supervisor of the company, there is no circumstance that he has been determined by the China Securities Regulatory Commission to be a person prohibited from entering the market and is still in the prohibition period, there is no circumstance that he has been publicly determined by the stock exchange to be unsuitable to serve as a supervisor of a listed company, he has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, and he is not a dishonest person subject to execution announced by the Supreme People's Court, and he meets the requirements of the Company Law and other relevant laws, regulations and regulations.

Ms. Guo Congzhao, Chinese nationality, no right of permanent residence abroad, born in November 1972, holds a master's degree in economics from Zhongnan University of Economics and Law, and is a Chinese certified public accountant. From August 1996 to September 1998, Ms. Guo Congzhao successively served as a cadre and deputy chief staff member of the Second Central Industry Division of the Department of Industry and Communications of the Ministry of Finance, during which she was assigned to work under the Finance Bureau of Pingquan County, Hebei Province from October 1996 to September 1997. From September 1998 to August 2001, he successively served as the principal staff member of the System Division and the Industrial Division of the Enterprise Department of the Economic and Trade Department of the Ministry of Finance. From August 2001 to August 2014, he successively served as the chief staff member, deputy director, researcher and director of the first division of the Enterprise Department of the Ministry of Finance, and from May 2006 to April 2007, he served as the deputy director of the district government office in the People's Government of Hangu District, Tianjin. From August 2014 to September 2017, he successively served as a director-level cadre of the Asset Management Department of the Ministry of Finance and the director of the State-owned Enterprise Reform Division. From September 2017 to September 2019, he successively served as the general manager and investment director of the equity investment department of China National Pharmaceutical Investment Co., Ltd., the investment director and general manager of the industrial development department of China National Pharmaceutical Investment Co., Ltd. from September 2019 to December 2019, the investment director of China National Pharmaceutical Investment Co., Ltd. since December 2019, and the deputy general manager (in charge of daily work) and chief financial officer of Sinopharm Private Equity Fund Management (Beijing) Co., Ltd. since April 2023. Since July 2018, he has served as a supervisor of the company.

As of the disclosure date, Ms. Guo Congzhao did not hold any shares in the Company. Ms. Guo Congzhao has no affiliation with other directors, supervisors and senior management of the Company. There is no circumstance that the Company Law prohibits him from serving as a supervisor of the company, there is no circumstance that he has been determined by the China Securities Regulatory Commission to be a person prohibited from entering the market and is still in the prohibition period, there is no circumstance that he has been publicly determined by the stock exchange to be unsuitable to serve as a supervisor of a listed company, he has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, and he is not a dishonest person subject to execution announced by the Supreme People's Court, and he meets the requirements of the Company Law and other relevant laws, regulations and regulations.

Attachment: The original text of the announcement